Navigation Links
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
Date:8/14/2009

ay develop technologies or products superior to orBec(R). Factors affecting the development and use of DOR201 and LPM(TM) are similar to those affecting orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-K. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
6. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
7. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
8. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
11. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- BioClinica®, Inc., a leading provider of outsourced clinical ... its experts are speaking at the 20th Annual ... held September 28 to October 1 in ... the innovative Compass technology, a risk-based monitoring ... earlier this year, is up for the Technology ...
(Date:9/17/2014)... PITTSBURGH , Sept. 17, 2014 ... maker of MD-Cu 29 antimicrobial copper, announces Gilmour ... points to the first EPA-registered antimicrobial solid touch surface ... copper is a reasonably priced surface that kills greater ... 2 hours of exposure. 1 ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
... , Jan. 12 Novavax, Inc. (Nasdaq: ... pre-clinical safety and efficacy study of its RSV vaccine candidate ... support an Investigational New Drug (IND) application to advance this ... into clinical development.  This vaccine candidate is composed of recombinant ...
... ... a standalone Windows® desktop application for viewing eCTD submissions created for any region. ... Marlborough, MA (PRWEB) January 12, ... for the life sciences industry, today announced the release of Datafarm VUE, a new addition ...
... ... VA, will discuss practical approaches to President Obama’s challenges to "find the needle in ... ... connect the dots” on the Christmas bomber in his recent address to the Nation. ...
Cached Biology Technology:NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 2NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 3NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 4NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate 5Datafarm Releases New Desktop-based Application for Multi-region Viewing of eCTD Submissions: Datafarm VUE 2NDIA's Biometrics Conference to Address Practical Approaches to the President's Challenge of 'Connecting the Dots' and Implementing $1B for New and Additional Security 2
(Date:9/16/2014)... school biology taught us that we inherit certain traits ... you could change how these genes play out by ... diet? That,s exactly what a team of researchers ... proposed through their research of epigenetics research. , ... chemically modifying DNA and histone proteins, which prevent permanent ...
(Date:9/16/2014)... own bacterial identity. That,s the conclusion of University of ... the genetic fingerprints of bacteria on 57 species of ... demonstrates for the first time that host plants from ... very different microbial communities on their leaves," said lead ... the UO,s Institute of Ecology and Evolution who is ...
(Date:9/16/2014)... 10-km diameter chunk of rock hit the Yukatan peninsula near ... force of 100 teratons of TNT. It left a crater ... global earthquakes and volcanism are widely accepted to have wiped ... the mammals. But what happened to the plants on which ... from the University of Arizona reveals that the meteorite impact ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... DALLAS May 20, 2008 Mutations in two ... the brain involved in sleep create a human-like insomnia ... found. The findings may help scientists better understand the ... This is one of the most dramatic ...
... exposure to chemicals is on the increase. From food ... with potentially-toxic substances could be affecting our health ... Nottingham are set to take part in one of ... on female mammals. Part of the Reproductive Effects of ...
... CITY Researchers have been unable to build an ... dream of ultrafast optical computers. But now, University of ... photonic crystals with the ideal, diamond-like structure: They are ... beetle from Brazil. It appears that a simple ...
Cached Biology News:Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2Do chemicals in the environment affect fertility? 2The photonic beetle 2The photonic beetle 3The photonic beetle 4The photonic beetle 5
...
Healthy animals 10-32 weeks of age, mixed gender and breed; collected on wet ice following USDA guidelines, using Alsevers solution at 1:2 dilution...
... The Zero Blunt TOPO ... the fastest and easiest ... than or equal to95%) ... products amplified with proofreading ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
Biology Products: